Company Overview and News

 
Sugar stocks slump as CCI imposes penalty on sugar mills, trade associations

2018-09-21 thehindubusinessline
Sugar stocks today fell as the Competition Commission of India has imposed a penalty of Rs 38 crore on 18 sugar mills and two trade associations, ISMA and EMAI, for rigging bids in joint tenders floated by public sector oil marketing companies.
BAJAJHIND BALRAMCHIN 500038 500032

 
Sugar stocks jump as govt may incentivise exports

2018-09-19 thehindubusinessline
Sugar stocks jumped 5-10 per cent after Reuters reported that the government is likely to consider a proposal to get sugar mills to export 5 million tonnes of sugar by incentivising overseas sales in the 2018/19 season.
BALRAMCHIN UTTAMSUGAR 532729 500119 500038 DHAMPURSUG

 
Balrampur Chini Mills Limited - Shareholders meeting

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
ILFS Transport, Avanti Feeds, Suzlon, Balrampur Chini top gainers among BSE Group A stocks

2018-09-17 moneycontrol
The Indian benchmark indices continued to trade in the red on Monday afternoon with the Nifty50 down 142 points while the Sensex was trading lower by 504 points at 37,586.
BALRAMCHIN SUZLON ZODIACLOTH AVANTI MONSANTO 507490 512573 532667 513023 524084 521163 500038 RANASUG SUEL NBVENTURES

 
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Sugar stocks extend gains, zoom 20% after government hikes ethanol price by 25%

2018-09-14 moneycontrol
Sugar stocks are rallying this Friday afternoon and have given robust gains after the government approved hiking the price of ethanol produced directly from sugarcane juice for blending in petrol by 25 percent.
MAWANASUG BALRAMCHIN 523371 532670 SAKHTISUG 507490 500038 RENUKA RANASUG 507315

 
Looking for momentum plays? Top three stocks which could give 15-23% return in 6 months

2018-09-13 moneycontrol
Equity benchmarks snapped their eight week’s winning streak as it witnessed profit booking amid concerns over a sharp depreciation in the rupee. Key observation since the beginning of 2018, each directional leg in the Nifty has lasted for seven to eight weeks.
BALRAMCHIN ALKEM 501455 539523 500038 GREAVESCOT

 
Ethanol price hike sweet for sugar mills but aftertaste could be bitter

2018-09-13 livemint
The government on Wednesday approved an increase in ethanol prices for the 2018-19 sugar season, starting October. The level of the price increase suggests that the centre wants to incentivize ethanol output and investments in capacity addition. But the industry may still be wary, given that these incentives were to paper over the structural cracks in the sugar industry, which may raise the risk of a volatile future.
BALRAMCHIN 500038

 
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Balrampur Chini Mills Limited - Shareholders meeting

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Balrampur Chini (Buy)

2018-08-11 thehindubusinessline
Balrampur Chini Mills (BCML) is one of the largest integrated sugar manufacturing company in India. It also offers molasses, industrial alcohol, ethanol, and bagasse. In addition, the company is involved in the generation and sale of electricity.
BALRAMCHIN 505200 ECQRY 500038 EICHERMOT

 
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Balrampur Chini Mills Limited - Outcome of Board Meeting

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

 
Balrampur Chini Mills Limited - Investor Presentation

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...